Bedside Clinical Question: When to use high dose vs low dose thiamine in alcohol use disorder (AUD)?
Background:
Wernicke’s encephalopathy is an acute, reversible brain disorder caused by thiamine deficiency, often due to chronic alcohol use. If left untreated, it can progress to Korsakoff’s syndrome, a chronic, irreversible condition marked by severe memory impairment.
Thiamine (vitamin B1) is a water soluble vitamin essential for energy metabolism, functioning as a cofactor in its active form, thiamine pyrophosphate. In individuals with AUD, thiamine deficiency is common due to poor dietary intake, impaired absorption, reduced liver storage, and increased renal loss.
Due to the high risk of Wernicke’s encephalopathy in patients with chronic alcohol use, thiamine should be administered prophylactically, even in the absence of confirmed deficiency.
Answer:
There is no universal consensus on thiamine dosing for Wernicke–Korsakoff syndrome; while moderate to high doses (e.g., 200–500 mg) are commonly used, evidence remains limited to guide exact dose, route, or duration.
Due to high rates of deficiency in alcohol use disorder, all patients should receive at least 100 mg thiamine supplementation, regardless of nutritional status.
High-risk patients should receive high-dose IV thiamine (500 mg three times daily for 2–3 days), then transition to oral therapy.
IV thiamine is preferred initially in at-risk patients for better absorption, while oral thiamine is used for maintenance once symptoms improve.
Conclusion:
All patients with chronic alcohol use should receive at least low-dose thiamine (100 mg IV/PO daily), even without confirmed deficiency.
High-dose thiamine (500 mg IV TID) is recommended for patients at risk of or showing signs of Wernicke’s encephalopathy (e.g., severe withdrawal, confusion, ataxia, delirium tremens).
Please refer to our ED guideline page for the EtOH guideline for more information.
References:
Praharaj SK, Munoli RN, Shenoy S, Udupa ST, Thomas LS. High-dose thiamine strategy in Wernicke-Korsakoff syndrome and related thiamine deficiency conditions associated with alcohol use disorder. Indian J Psychiatry. 2021;63(2):121-126. Doi:10.4103/psychiatry.IndianJPsychiatry_440_20.
Latt N, Dore G. Thiamine in the treatment of Wernicke encephalopathy in patients with alcohol use disorders. Intern Med J. 2014;44(9):911-915. doi:10.1111/imj.12522.
Alcohol and Drug Foundation. Preventing and treating Wernicke’s encephalopathy. Australian Guidelines for the Treatment of Alcohol Problems. Updated June 2021. https://alcoholtreatmentguidelines.com.au/wernickekorsakoffs-syndrome/preventing-and-treating-wernickes-encephalopathy.
Latt, N. and Dore, G. (2014), Thiamine in Wernicke's encephalopathy. Intern Med J, 44: 911-915. https://doi.org/10.1111/imj.12522
Authored by Alejandra Alvarez PharmD (PGY1) and Joanne Routsolias PharmD